Category: Pα+ - Psychedelic Alpha

Read more about the article Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could Streamline Schedule I Research

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could Streamline Schedule I Research

Post published:July 25, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article June 2025 Psychedelic Patent Update

June 2025 Psychedelic Patent Update

Post published:July 24, 2025
Post category:Psychedelic Patent Analysis Pα+

Read more about the article Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Plasticity, Psychotherapy, and Perception (Part 1)

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Plasticity, Psychotherapy, and Perception (Part 1)

Post published:July 23, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD; Longevity Crowd Hypes Psilocybin Study; Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch?

Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD; Longevity Crowd Hypes Psilocybin Study; Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch?

Post published:July 14, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Psychedelic Funding Update: Q2 2025

Psychedelic Funding Update: Q2 2025

Post published:July 9, 2025
Post category:Analysis Pα+

Read more about the article From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

Post published:July 7, 2025
Post category:Interviews Pα+

Read more about the article Oregon Psilocybin Services Tracker: Q1 2025

Oregon Psilocybin Services Tracker: Q1 2025

Post published:July 4, 2025
Post category:Analysis Pα+

Read more about the article Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Post published:July 1, 2025
Post category:Analysis News Pα+

Read more about the article Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Post published:July 1, 2025
Post category:Interviews Pα+

Read more about the article Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

Post published:June 28, 2025
Post category:Analysis News Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.